| Literature DB >> 29403802 |
Matthias D'Hondt1, Bert Gevaert1, Sofie Stalmans1, Sylvia Van Dorpe1, Evelien Wynendaele1, Kathelijne Peremans2, Christian Burvenich2, Bart De Spiegeleer1.
Abstract
Different fused-core stationary phase chemistries (C18, Amide, Phenyl-hexyl and Peptide ES-C18) were used for the analysis of 21 structurally representative model peptides. In addition, the effects of the mobile phase composition (ACN or MeOH as organic modifier; formic acid or acetic acid, as acidifying component) on the column selectivity, peak shape and overall chromatographic performance were evaluated. The RP-amide column, combined with a formic acid-acetonitrile based gradient system, performed as best. A peptide reversed-phase retention model is proposed, consisting of 5 variables: log SumAA, log Sv, clog P, log nHDon and log nHAcc. Quantitative structure-retention relationship (QSRR) models were constructed for 16 different chromatographic systems. The accuracy of this peptide retention model was demonstrated by the comparison between predicted and experimentally obtained retention times, explaining on average 86% of the variability. Moreover, using an external set of 5 validation peptides, the predictive power of the model was also demonstrated. This peptide retention model includes the novel in-silico calculated amino acid descriptor, AA, which was calculated from log P, 3D-MoRSE, RDF and WHIM descriptors.Entities:
Keywords: Fused-core (core-shell, core-enhanced, poro-shell, HALO®) stationary phases; In-silico amino acid descriptor; Peptides; RP-HPLC peptide retention model
Year: 2012 PMID: 29403802 PMCID: PMC5760978 DOI: 10.1016/j.jpha.2012.11.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Properties of the HALO fused-core stationary phases.
| Phase | Bonded phase | Pore size (Å) | Surface area (m²/g) | Bonding density (μmol/m²) | Endcapped | Base deactivation | Dimensions (l×i.d.) (mm) | pH range |
|---|---|---|---|---|---|---|---|---|
| C18 | 90 | 150 | 3.5 | Yes | Yes | 150×4.6 | 2–9 | |
| Peptide ES-C18 | 160 | 80 | 2.0 | No | – | 75×3.0 | 1–9 | |
| RP-amide | 90 | 150 | 3.0 | Yes | Yes | 150×4.6 | 2–9 | |
| Phenyl-hexyl | 90 | 150 | 3.4 | Yes | Yes | 75×3.0 | 2–9 | |
| HILIC | – | 90 | 150 | – | – | – | 100×3.0 | 2–9 |
Overview of selected peptides (21 model-building and 5 validation peptides).
| Peptide | MW (g/mol) | log P | pI |
|---|---|---|---|
| Adrenomedullin | 5730.46 | −38.53 | 10.39 |
| Amylin | 3921.43 | −26.06 | 10.81 |
| cHP | 234.26 | −1.26 | 8.81 |
| CRH | 4758.50 | −20.78 | 5.59 |
| CTOP | 1062.27 | −1.40 | 9.41 |
| Dermorphin | 802.88 | −1.24 | 9.16 |
| Des-octanoyl ghrelin | 3188.65 | −21.81 | 10.67 |
| DPDPE | 645.79 | 0.87 | 5.70 |
| Endomorphin-1 | 610.71 | 1.76 | 8.61 |
| GALP rat | 6502.44 | −31.07 | 10.17 |
| Kyotorphin | 337.38 | −0.07 | 8.74 |
| LHRH | 1183.29 | −4.14 | 8.08 |
| Mouse Obestatin | 2516.85 | −12.96 | 9.81 |
| MCH | 2386.84 | −5.52 | 8.85 |
| Met5-Enkephalin | 573.66 | −0.69 | 5.82 |
| Orexin A | 3561.14 | −17.35 | 9.71 |
| RC-160 | 1131.38 | 1.50 | 9.73 |
| SB-Aba | 580.68 | 0.05 | 10.28 |
| UCN-I | 4708.04 | −19.32 | 5.70 |
| VDE243 | 671.75 | −0.62 | 5.87 |
| VIP | 3326.83 | −16.19 | 9.71 |
| Endomorphin-2 | 571.68 | 1.99 | 8.61 |
| Neuropeptide Y | 4254.70 | −17.73 | 8.05 |
| Phe13Tyr19-MCH | 2434.88 | −4.71 | 8.85 |
| TAPP | 545.64 | 2.62 | 8.61 |
| Urocortin II | 4153.94 | −14.84 | 10.57 |
Fig. 1Typical chromatograms: MCH, UCN-1 and dermorphin (from top to bottom) on HALO RP-amide column, using formic acid–acetonitrile based chromatography.
Retention models obtained on the four fused-core columns using multiple linear regression.
| MP | Retention models | Experimental vs. predicted model fit predicted | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptide ES-C18 | FA | 0.818 | 13.448 | −3.698 | 8.352 | 0.075 | −3.030 | −9.095 | 8.096 | 0.818 | 0.694 |
| FM | 0.913 | 31.317 | −5.389 | 13.011 | 0.101 | −3.695 | −10.925 | 9.082 | 0.912 | 0.670 | |
| AA | 0.826 | 14.210 | −3.582 | 9.932 | 0.089 | −3.694 | −9.935 | 8.631 | 0.825 | 0.842 | |
| AM | 0.916 | 32.603 | −7.162 | 12.847 | 0.128 | −2.830 | −12.110 | 10.410 | 0.916 | 0.632 | |
| RP-amide | FA | 0.817 | 13.385 | −7.445 | 14.750 | 0.140 | −5.845 | −17.287 | 16.202 | 0.817 | 1.086 |
| FM | 0.845 | 16.401 | −10.615 | 30.793 | 0.217 | −13.321 | −29.263 | 26.367 | 0.845 | 2.119 | |
| AA | 0.857 | 17.956 | −5.582 | 18.575 | 0.145 | −9.002 | −20.325 | 18.815 | 0.857 | 1.104 | |
| AM | 0.857 | 18.003 | −15.790 | 32.709 | 0.271 | −13.783 | −39.538 | 36.968 | 0.857 | 1.787 | |
| Phenyl-hexyl | FA | 0.796 | 11.736 | −1.215 | 7.356 | 0.044 | −3.315 | −5.332 | 4.209 | 0.797 | 0.707 |
| FM | 0.901 | 27.412 | −3.360 | 14.479 | 0.083 | −5.777 | −10.382 | 8.278 | 0.901 | 0.750 | |
| AA | 0.800 | 11.967 | −2.466 | 9.910 | 0.081 | −4.195 | −9.285 | 7.835 | 0.800 | 0.926 | |
| AM | 0.890 | 24.202 | −6.223 | 14.274 | 0.115 | −4.057 | −13.080 | 10.724 | 0.890 | 0.848 | |
| C18 | FA | 0.834 | 15.023 | −7.006 | 14.159 | 0.113 | −5.683 | −16.758 | 15.644 | 0.833 | 0.970 |
| FM | 0.892 | 24.810 | −10.790 | 29.263 | 0.181 | −11.703 | −29.591 | 26.210 | 0.892 | 1.498 | |
| AA | 0.851 | 17.175 | −6.211 | 18.308 | 0.124 | 8.671 | −21.040 | 19.491 | 0.851 | 1.125 | |
| AM | 0.903 | 27.875 | −14.259 | 30.967 | 0.220 | −12.470 | −35.679 | 32.723 | 0.903 | 1.266 | |
MP=mobile phase, FA=formic acid–acetonitrile, FM=formic acid–methanol, AA=acetic acid–acetonitrile, AM=acetic acid–methanol.
Fig. 2Peptide retention model.
Fig. 3Predictive power of the peptide retention model.